Cargando…
A randomized, double‐blind trial of triheptanoin for drug‐resistant epilepsy in glucose transporter 1 deficiency syndrome
OBJECTIVE: This study was undertaken to evaluate efficacy and long‐term safety of triheptanoin in patients >1 year old, not on a ketogenic diet, with drug‐resistant seizures associated with glucose transporter 1 deficiency syndrome (Glut1DS). METHODS: UX007G‐CL201 was a randomized, double‐blind,...
Autores principales: | Striano, Pasquale, Auvin, Stéphane, Collins, Abigail, Horvath, Rita, Scheffer, Ingrid E., Tzadok, Michal, Miller, Ian, Kay Koenig, Mary, Lacy, Adrian, Davis, Ronald, Garcia‐Cazorla, Angela, Saneto, Russell P., Brandabur, Melanie, Blair, Susan, Koutsoukos, Tony, De Vivo, Darryl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546029/ https://www.ncbi.nlm.nih.gov/pubmed/35441706 http://dx.doi.org/10.1111/epi.17263 |
Ejemplares similares
-
Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency
por: Engelstad, Kristin, et al.
Publicado: (2021) -
Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020) -
Correction to: Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020) -
Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
por: Borges, Karin, et al.
Publicado: (2019) -
Open‐label long‐term treatment of add‐on triheptanoin in adults with drug‐resistant epilepsy
por: Borges, Karin, et al.
Publicado: (2020)